<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style> Enap catalog › Details for: Organizational reputation and jurisdictional claims :
Normal view MARC view ISBD view

Organizational reputation and jurisdictional claims : the case of the U.S. food and drug administration

By: MAOR, Moshe.
Material type: materialTypeLabelArticlePublisher: Malden : Wiley-Blackwell, jan. 2010Subject(s): Tecnologia da Informação | Regulação | SaúdeGovernance: An International Journal of Policy, Administration, and Institutions 23, 1, p. 133-160Abstract: When do regulatory agencies expand, following the emergence of novel technologies? This article presents a verbal model that suggests that a regulator is most likely to announce that it has statutory authority to regulate a novel technology when its reputation is at stake. This is most likely to occur when (1) new information becomes available to the regulator regarding the seriousness of the anticipated harm of a novel technology, or (2) a rival regulator attempts to formalize its regulatory authority or fails to do so although officially required to. A historical–institutional analysis of the temporal process leading to jurisdictional claims by the U.S. Food and Drug Administration over gene therapy, laboratory-developed complex diagnostic tests, human tissue transplants, and human cloning supports the model's prediction
Tags from this library: No tags from this library for this title. Log in to add tags.
    average rating: 0.0 (0 votes)
No physical items for this record

When do regulatory agencies expand, following the emergence of novel technologies? This article presents a verbal model that suggests that a regulator is most likely to announce that it has statutory authority to regulate a novel technology when its reputation is at stake. This is most likely to occur when (1) new information becomes available to the regulator regarding the seriousness of the anticipated harm of a novel technology, or (2) a rival regulator attempts to formalize its regulatory authority or fails to do so although officially required to. A historical–institutional analysis of the temporal process leading to jurisdictional claims by the U.S. Food and Drug Administration over gene therapy, laboratory-developed complex diagnostic tests, human tissue transplants, and human cloning supports the model's prediction

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer

Escola Nacional de Administração Pública

Escola Nacional de Administração Pública

Endereço:

  • Biblioteca Graciliano Ramos
  • Funcionamento: segunda a sexta-feira, das 9h às 19h
  • +55 61 2020-3139 / biblioteca@enap.gov.br
  • SPO Área Especial 2-A
  • CEP 70610-900 - Brasília/DF
<
Acesso à Informação TRANSPARÊNCIA

Powered by Koha